Antimicrobial Agents Practice Questions

Q: Which of the following anti-retroviral drugs is contraindicated in pregnancy?

Efavirenz. **Explanation:** The correct answer is **Efavirenz**. **Why Efavirenz is the correct answer:** Efavirenz is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Historically, it has been classified as **FDA Pregnancy Category D** due to its potential **teratogenic effects**. Animal studies and early human reports suggested an increased risk of **neural tube defects** (like myelomeningocele) if administered during the first trimester (the period of organogenesis). While recent meta-analyses suggest the risk may be lower than previously feared, standard pharmacological teaching for exams like NEET-PG continues to highlight Efavirenz as the drug to avoid in pregnancy compared to safer alternatives. **Why the other options are incorrect:** * **Zidovudine (AZT):** This is the "gold standard" and the most extensively studied drug for preventing mother-to-child transmission (PMTCT). It is considered safe and is often used intrapartum. * **Lamivudine (3TC):** A Nucleoside Reverse Transcriptase Inhibitor (NRTI) that is a core component of most Highly Active Antiretroviral Therapy (HAART) regimens in pregnancy due to its excellent safety profile. * **Nelfinavir:** A Protease Inhibitor (PI) that was historically used in pregnancy. While newer PIs like Lopinavir/Ritonavir are now preferred, Nelfinavir is not contraindicated. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for PMTCT:** The current WHO/NACO recommendation for pregnant women is a fixed-dose combination of **Tenofovir (TDF) + Lamivudine (3TC) + Dolutegravir (DTG)**. * **Zidovudine** is specifically used to prevent transmission during labor and is given to the neonate post-exposure. * **Nevirapine** is an NNRTI that can be used in pregnancy but requires monitoring for hepatotoxicity and Stevens-Johnson Syndrome (SJS).

Q: What is the basis for combining ritonavir with lopinavir?

C4P3A4 inhibition by ritonavir. **Explanation:** The combination of **Ritonavir and Lopinavir** (marketed as Kaletra) is a classic example of **pharmacokinetic boosting**. **1. Why Option B is Correct:** Lopinavir is a potent Protease Inhibitor (PI) used in HIV treatment, but it has poor oral bioavailability because it is rapidly metabolized by the hepatic enzyme **CYP3A4**. Ritonavir is also a Protease Inhibitor, but it is one of the most potent inhibitors of the CYP3A4 isoenzyme known. When a low "booster" dose of ritonavir is added, it inhibits the metabolism of lopinavir, significantly increasing its plasma concentration, half-life, and therapeutic efficacy. **2. Why Other Options are Incorrect:** * **Option A:** While they are chemically compatible in a single formulation, pharmaceutical compatibility is not the therapeutic rationale for the combination. * **Option C:** Ritonavir actually has a relatively short half-life (~3–5 hours). Its utility lies in its enzyme-inhibiting property, not its own persistence in the body. * **Option D:** Ritonavir does not counteract lopinavir’s side effects; in fact, ritonavir itself is often associated with significant GI distress and lipid elevations, which is why it is used primarily as a booster rather than a primary PI. **Clinical Pearls for NEET-PG:** * **Pharmacokinetic Boosting:** This concept is also used with **Cobicistat**, a drug that inhibits CYP3A4 but has no inherent antiviral activity. * **Protease Inhibitor (PI) Class Suffix:** All drugs in this class end in **"-navir"** (e.g., Atazanavir, Darunavir). * **Metabolic Side Effects:** PIs are high-yield for causing **lipodystrophy** (buffalo hump), insulin resistance, and hyperlipidemia. * **Drug Interactions:** Because ritonavir is a potent CYP3A4 inhibitor, it has numerous dangerous drug-drug interactions (e.g., with statins, midazolam, and rifampin).

Q: Renal toxicity, though generally negligible, is associated with which of the following medications?

Tenofovir. **Explanation:** **Tenofovir** (specifically Tenofovir Disoproxil Fumarate or TDF) is a Nucleotide Reverse Transcriptase Inhibitor (NRTI) used in the treatment of HIV and Hepatitis B. Its primary dose-limiting toxicity is **nephrotoxicity**, which typically manifests as **proximal renal tubular dysfunction (Fanconi Syndrome)**. 1. **Why Tenofovir is correct:** Tenofovir is actively transported into the proximal convoluted tubule cells by organic anion transporters (OAT1/3). Accumulation within these cells leads to mitochondrial DNA depletion and dysfunction. This results in impaired reabsorption of glucose, amino acids, uric acid, and phosphate, leading to proteinuria and, in severe cases, acute kidney injury or chronic kidney disease. 2. **Why other options are incorrect:** * **Entecavir:** It is a potent guanosine analogue for HBV. While it requires dose adjustment in renal impairment, it is not inherently nephrotoxic. * **Telbivudine:** This drug is primarily associated with **myopathy** and increased creatine kinase (CK) levels, rather than renal toxicity. * **Lamivudine:** It is generally well-tolerated. Its main side effects include headache and nausea; it does not cause direct renal damage. **High-Yield Clinical Pearls for NEET-PG:** * **Tenofovir Alafenamide (TAF):** A newer prodrug of Tenofovir that achieves higher intracellular concentrations with much lower plasma levels, significantly reducing the risk of renal toxicity and bone mineral density loss compared to TDF. * **Fanconi Syndrome Triad:** Look for phosphaturia (leading to osteomalacia), glycosuria (with normal blood sugar), and metabolic acidosis in a patient on Tenofovir. * **Monitoring:** Patients on TDF should have their serum creatinine and phosphorus levels monitored regularly.

Q: Which of the following antimicrobial agents is not bacteriostatic?

Vancomycin. ### Explanation **Core Concept:** Antimicrobial agents are classified based on their effect on bacteria: **Bacteriostatic** drugs inhibit growth and replication (requiring the host’s immune system to clear the infection), while **Bactericidal** drugs actively kill the bacteria. **Why Vancomycin is the Correct Answer:** **Vancomycin** is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the **D-Ala-D-Ala** terminus of nascent peptidoglycan chains. Like most cell wall synthesis inhibitors (e.g., Penicillins, Cephalosporins), it is **bactericidal**. It causes cell lysis, making it the only bactericidal agent among the options provided. **Analysis of Incorrect Options:** * **Linezolid (Option A):** An oxazolidinone that inhibits protein synthesis by binding to the 50S subunit (specifically preventing the formation of the 70S initiation complex). It is **bacteriostatic** against Staphylococci and Enterococci (though it shows bactericidal activity against *S. pneumoniae*). * **Clindamycin (Option B):** A lincosamide that inhibits protein synthesis by binding to the 50S ribosomal subunit. It is primarily **bacteriostatic**. * **Erythromycin (Option C):** A macrolide that inhibits protein synthesis at the 50S subunit. Macrolides are classic examples of **bacteriostatic** agents. **NEET-PG High-Yield Pearls:** * **Mnemonic for Bactericidal drugs:** "**V**ery **F**inely **P**en**C**illed **A**t **B**edside" (**V**ancomycin, **F**luoroquinolones, **P**enicillins, **C**ephalosporins, **A**minoglycosides, **B**acitracin). * **Exception:** Aminoglycosides are the only protein synthesis inhibitors that are primarily bactericidal. * **Clinical Note:** Vancomycin is the drug of choice for **MRSA**. Rapid IV infusion can cause "**Red Man Syndrome**" due to histamine release (not an allergy).

Q: What is the empirical treatment for pneumococcal meningitis?

Vancomycin + ceftriaxone. The empirical treatment for suspected bacterial meningitis must cover the most common and aggressive pathogens, primarily *Streptococcus pneumoniae* and *Neisseria meningitidis* [2]. **1. Why Option D is Correct:** The current standard of care for empirical treatment of pneumococcal meningitis is the combination of **Vancomycin plus a third-generation cephalosporin (Ceftriaxone or Cefotaxime)** [1]. This is due to the rising global prevalence of penicillin-resistant and cephalosporin-resistant *S. pneumoniae* [1]. Vancomycin provides synergistic coverage against highly resistant strains, while Ceftriaxone offers excellent CSF penetration and covers *N. meningitidis* and *H. influenzae* [1]. **2. Why Other Options are Incorrect:** * **Option A (Penicillin G):** While historically the drug of choice, it is no longer used empirically due to widespread high-level penicillin resistance in *S. pneumoniae*. It is only used if the isolate is proven to be susceptible. * **Options B & C (Doxycycline/Tetracycline):** These are bacteriostatic agents and have poor penetration into the cerebrospinal fluid (CSF). They are not indicated for the treatment of acute bacterial meningitis. **3. NEET-PG High-Yield Pearls:** * **Dexamethasone:** Should be administered **before or with the first dose** of antibiotics to reduce neurological sequelae (like hearing loss) caused by the inflammatory response to bacterial lysis [2]. * **Listeria Coverage:** If the patient is >50 years old or immunocompromised, **Ampicillin** must be added to the regimen to cover *Listeria monocytogenes* [2]. * **Ceftriaxone Caution:** Avoid Ceftriaxone in neonates; use Cefotaxime instead to prevent biliary sludging and kernicterus. * **Drug of Choice (DOC):** Once sensitivity results are back, if the strain is penicillin-susceptible, Penicillin G becomes the DOC.

Q: Which anti-tuberculosis agent causes orange-colored urine?

Rifampicin. **Explanation:** **Rifampicin** is a semi-synthetic derivative of rifamycin and a key bactericidal drug in the DOTS regimen. The correct answer is Rifampicin because it is a **zwitterionic compound with a characteristic red-orange color**. After administration, it is excreted through urine, sweat, tears, and saliva, imparting a harmless **orange-red discoloration** to these body fluids. **Why the other options are incorrect:** * **Isoniazid (INH):** Its primary side effects are peripheral neuropathy (due to Vitamin B6 deficiency) and hepatotoxicity. It does not cause pigment changes in secretions. * **Streptomycin:** An aminoglycoside that primarily causes ototoxicity (vestibular damage) and nephrotoxicity. * **Pyrazinamide:** Known for causing hyperuricemia (leading to gouty arthritis) and hepatotoxicity, but it does not discolor urine. **Clinical Pearls for NEET-PG:** 1. **Patient Counseling:** Always advise patients starting Rifampicin about orange urine to prevent unnecessary anxiety and improve compliance. It can also permanently stain soft contact lenses. 2. **Mechanism of Action:** Rifampicin inhibits **DNA-dependent RNA polymerase**, thereby blocking bacterial RNA synthesis. 3. **Enzyme Induction:** Rifampicin is a potent **Cytochrome P450 inducer**, leading to significant drug interactions (e.g., reducing the efficacy of oral contraceptives and warfarin). 4. **Resistance:** Resistance develops rapidly if used as monotherapy due to mutations in the *rpoB* gene.

Q: What is the drug of choice for brucellosis?

Doxycycline. **Explanation:** **Brucellosis** is a zoonotic infection caused by *Brucella* species, which are facultative intracellular organisms. Effective treatment requires drugs with high intracellular penetration and a low risk of relapse. **Why Doxycycline is the Correct Answer:** **Doxycycline** is the backbone of brucellosis treatment. Due to its high lipid solubility, it achieves excellent intracellular concentrations, which is essential for eradicating the bacteria residing within macrophages. However, when used as monotherapy, relapse rates are high. Therefore, the **WHO-recommended regimen** (and the gold standard) is **Doxycycline (100 mg BID for 6 weeks) + Rifampin (600–900 mg/day for 6 weeks)**. Alternatively, Doxycycline can be combined with Streptomycin (IM for 2–3 weeks). **Why Other Options are Incorrect:** * **A. Chloramphenicol:** While it has good intracellular penetration, it is not a first-line agent due to the risk of bone marrow toxicity (aplastic anemia) and higher relapse rates compared to tetracyclines. * **B. Erythromycin:** Macrolides have poor *in vitro* activity against *Brucella* and are clinically ineffective for this condition. * **D. Cefuroxime:** Second-generation cephalosporins do not have the necessary intracellular reach or specific activity required to treat brucellosis. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Doxycycline + Rifampin (for 6 weeks). * **In Pregnancy/Children (<8 years):** Doxycycline is contraindicated. The DOC is **Trimethoprim-Sulfamethoxazole (TMP-SMZ) + Rifampin**. * **Neurobrucellosis/Endocarditis:** Requires a triple regimen (Doxycycline + Rifampin + Aminoglycoside/Ceftriaxone) for a prolonged duration (3–6 months). * **Common Presentation:** Undulant fever (fever that rises and falls like waves), profuse sweating, and hepatosplenomegaly.

Q: All of the following are used in the treatment of visceral leishmaniasis except:

Hydroxychloroquine. **Explanation:** Visceral Leishmaniasis (Kala-azar) is caused by *Leishmania donovani*. The correct answer is **Hydroxychloroquine**, as it is an antimalarial and immunomodulatory agent used in conditions like Malaria, SLE, and Rheumatoid Arthritis, but it has **no clinical efficacy** against *Leishmania* species. **Analysis of Options:** * **Miltefosine:** This is the **first and only oral drug** approved for visceral leishmaniasis. It acts by interfering with cell signaling pathways and membrane synthesis. It is highly effective but contraindicated in pregnancy due to teratogenicity. * **Paromomycin:** An aminoglycoside antibiotic that inhibits protein synthesis. It is used as an injectable treatment for Kala-azar and is known for being cost-effective, though it carries risks of ototoxicity and nephrotoxicity. * **Sitamaquine:** An oral 8-aminoquinoline derivative (currently under investigation/limited use) that has shown efficacy against the visceral form of the disease by interfering with the parasite's mitochondrial function. **High-Yield NEET-PG Pearls:** 1. **Drug of Choice:** **Liposomal Amphotericin B** is currently the preferred treatment due to its high efficacy and low toxicity (single-dose regimen is often used in India). 2. **Miltefosine:** Must be avoided in pregnancy; female patients should use contraception for 5 months post-treatment. 3. **Sodium Stibogluconate (Pentavalent Antimonials):** Formerly the mainstay of treatment, but now largely abandoned in regions like Bihar, India, due to widespread resistance and cardiotoxicity (Q-T prolongation). 4. **Post-Kala-azar Dermal Leishmaniasis (PKDL):** Usually treated with prolonged courses of Miltefosine or Amphotericin B.

Q: Merimepodib is intended for use as:

Antiviral. **Explanation:** **Merimepodib** is a potent, non-competitive inhibitor of the enzyme **Inosine Monophosphate Dehydrogenase (IMPDH)**. This enzyme is crucial for the *de novo* synthesis of guanosine nucleotides. By inhibiting IMPDH, Merimepodib depletes intracellular GTP pools, which are essential for viral RNA and DNA synthesis. 1. **Why Antiviral is Correct:** Merimepodib has demonstrated broad-spectrum antiviral activity. It was primarily developed to enhance the efficacy of Ribavirin and Interferon-alpha in the treatment of **Chronic Hepatitis C (HCV)**. By reducing GTP levels, it forces the viral polymerase to incorporate Ribavirin (a guanosine analog) more frequently, leading to lethal mutagenesis of the virus. It has also been investigated for activity against other viruses, including Zika and SARS-CoV-2. 2. **Why other options are incorrect:** * **Antifungal:** While some IMPDH inhibitors are studied for antifungal properties, Merimepodib is specifically categorized and clinically trialed as an antiviral agent. * **Antipsychotic:** Antipsychotics typically target dopamine (D2) or serotonin receptors; Merimepodib has no activity in the central nervous system related to psychosis. * **Immunomodulator:** Although other IMPDH inhibitors like **Mycophenolate Mofetil** are used as immunosuppressants (by inhibiting T and B cell proliferation), Merimepodib is specifically optimized for its antiviral synergy. **Clinical Pearls for NEET-PG:** * **Mechanism:** IMPDH Inhibitor (similar to Ribavirin and Mycophenolate). * **Synergy:** Often tested in the context of "Ribavirin-sparing" or "Ribavirin-enhancing" strategies for HCV. * **Key Association:** If you see "IMPDH inhibitor" in an antiviral context, think Merimepodib or Ribavirin.

Question 1

Which of the following anti-retroviral drugs is contraindicated in pregnancy?

Accepted Answer

Efavirenz

Answer

Lamivudine

Answer

Nelfinavir

Answer

Zidovudine

Question 2

What is the basis for combining ritonavir with lopinavir?

Accepted Answer

C4P3A4 inhibition by ritonavir

Answer

Pharmaceutical compatibility

Answer

Long elimination half-life of ritonavir

Answer

Ability to counteract side-effects of lopinavir

Question 3

Renal toxicity, though generally negligible, is associated with which of the following medications?

Accepted Answer

Tenofovir

Answer

Entecavir

Answer

Telbivudine

Answer

Lamivudine

Question 4

A 45-year-old HIV-1 positive male was started on a cART regimen of Tenofovir-Emtricitabine-Efavirenz. After 9 months, he developed Efavirenz resistance, which led to failure of therapy. Which of the following drugs of the same class can be used in place of Efavirenz?

Accepted Answer

Etravirine

Answer

Delavirdine

Answer

Nelfinavir

Answer

Nevirapine

Question 5

Which of the following antimicrobial agents is not bacteriostatic?

Accepted Answer

Vancomycin

Answer

Linezolid

Answer

Clindamycin

Answer

Erythromycin

Question 6

What is the empirical treatment for pneumococcal meningitis?

Accepted Answer

Vancomycin + ceftriaxone

Answer

Penicillin G

Answer

Doxycycline

Answer

Tetracycline

Question 7

Which anti-tuberculosis agent causes orange-colored urine?

Accepted Answer

Rifampicin

Answer

Isoniazid

Answer

Streptomycin

Answer

Pyrazinamide

Question 8

What is the drug of choice for brucellosis?

Accepted Answer

Doxycycline

Answer

Chloramphenicol

Answer

Erythromycin

Answer

Cefuroxime

Question 9

All of the following are used in the treatment of visceral leishmaniasis except:

Accepted Answer

Hydroxychloroquine

Answer

Sitamaquine

Answer

Paromomycin

Answer

Miltefosine

Question 10

Merimepodib is intended for use as:

Accepted Answer

Antiviral

Answer

Antifungal

Answer

Antipsychotic

Answer

Immunomodulator

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?